Skip to main content
Premium Trial:

Request an Annual Quote

CLC Bio, Two Danish Groups to Develop Software for RNA Disease Studies

NEW YORK (GenomeWeb News) — CLC Bio will work with two Danish research groups to design bioinformatic algorithms to study the molecular structure and evolution of certain viruses, the company said today.
 
CLC Bio said the $2.5 million, four-year project, called “PC Mini Grids for Prediction of Viral RNA Structure and Evolution,” will be conducted with the IT University of Copenhagen and the Department of Molecular Biology at the University of Aarhus.
 
Half of the funding for the project will come from the Danish Council for Strategic Research. The other half will come from the universities and from CLC Bio.
 
The company will help the universities to design a “collaborative, peer-to-peer software architecture” that will be used to research RNA-based diseases such as HIV, SARS, and avian flu, CLC Bio said.
 
The project aims to develop better, more user-friendly software for RNA researchers to use for theoretical analysis and in the lab, the company said.
 
The software will help scientists “get better RNA-research results in less time,” and allow them to conduct analysis on a standard computer, the company said.

Filed under

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.